X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
care and treatment (3) 3
chemotherapy (3) 3
disease-free survival (3) 3
humans (3) 3
index medicus (3) 3
middle aged (3) 3
survival (3) 3
adult (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
cancer (2) 2
cancer therapies (2) 2
female (2) 2
hematology, oncology and palliative medicine (2) 2
lymphoma, mantle-cell - drug therapy (2) 2
lymphomas (2) 2
maintenance (2) 2
male (2) 2
oncology (2) 2
patient outcomes (2) 2
retreatment (2) 2
rituximab (2) 2
studies (2) 2
survival rate (2) 2
treatment outcome (2) 2
abridged index medicus (1) 1
advanced follicular lymphoma (1) 1
aged, 80 and over (1) 1
anemia (1) 1
anemia - chemically induced (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antibodies, monoclonal, murine-derived - administration & dosage (1) 1
antibodies, monoclonal, murine-derived - adverse effects (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
article (1) 1
aspartate aminotransferase (1) 1
aspartate aminotransferases - blood (1) 1
b-cell (1) 1
bendamustine (1) 1
bendamustine hydrochloride (1) 1
bendamustine hydrochloride - administration & dosage (1) 1
bendamustine hydrochloride - adverse effects (1) 1
bone marrow (1) 1
breast cancer (1) 1
breast neoplasms - chemistry (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - pathology (1) 1
breast neoplasms, male - chemistry (1) 1
breast neoplasms, male - drug therapy (1) 1
breast neoplasms, male - pathology (1) 1
bridged-ring compounds - administration & dosage (1) 1
capecitabine - administration & dosage (1) 1
capecitabine - adverse effects (1) 1
combination (1) 1
comparative analysis (1) 1
coronary artery (1) 1
cyclophosphamide (1) 1
cyclophosphamide - administration & dosage (1) 1
cyclophosphamide - adverse effects (1) 1
cytotoxicity (1) 1
diarrhea (1) 1
diarrhea - chemically induced (1) 1
disease (1) 1
docetaxel (1) 1
doxorubicin - administration & dosage (1) 1
doxorubicin - adverse effects (1) 1
drug therapy (1) 1
encephalopathy (1) 1
epidermal growth factor (1) 1
erbb-2 protein (1) 1
fludarabine (1) 1
follicular lymphoma (1) 1
guidelines (1) 1
hand-foot syndrome - etiology (1) 1
heart diseases (1) 1
hematology (1) 1
ii multicenter (1) 1
infection - chemically induced (1) 1
infusions, intravenous (1) 1
internal medicine (1) 1
lapatinib (1) 1
leukemia (1) 1
low-grade (1) 1
lymphoma (1) 1
maytansine - adverse effects (1) 1
maytansine - analogs & derivatives (1) 1
maytansine - therapeutic use (1) 1
medical prognosis (1) 1
medicine, general & internal (1) 1
metabolic disorders (1) 1
metastases (1) 1
metastasis (1) 1
motivation (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 57 - 66
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.